Novartis publishes long-term data from SMA gene therapy

Novartis has produced data demonstrating its Zolgensma gene therapy produces long term benefits in the rare muscle wasting disease spinal muscular atrophy – information that will be closely

Biogen and Sangamo work on Parkinson's and Alzheimer's gene ...

Biogen and Sangamo have begun a collaboration to develop gene regulation therapies for neurological diseases including Parkinson’s and Alzheimer’s in a collaboration worth more than $2.7 bi

First UK patients get Novartis’ Luxturna gene therapy for bl...

How cell and gene therapies are transforming pharma deal-mak...

After decades of clinical research targeting development of more “personalised” medicines, the biotechnology sector is now starting to deliver with the first generation of promising new cel

Inborn Errors of Metabolism Drug Development Summit 2020

Inborn Errors of Metabolism Summit

UK biotech PhoreMost to work with Otsuka on gene therapy pro...

Building on an R&D tie-up with an Indian stem cell institution last year, UK biotech PhoreMost has begun a collaboration with Japan’s Otsuka working on several gene therapy projects.